Abstract: Monoclonal antibodies that recognize a stage-specifc antigen on immature human marrow cells are provided. These antibodies are useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marror transplantation. Cell suspensions containing human pluripotent lympho-hematopoietic stem cells are also provided, as well as theraputic methods employing the cell suspensions.

Abstract: Factor-dependent cell line, HU-01, provides the first in vitro system in which human CD34 positive hematopoietic cells have been induced to undergo complete differentiation into enucleated hemoglobin-containing erythrocytes. HU-01 cells may provide a source of monoclonal antibodies useful for early diagnosis and possible treatment of human leukemia conditions, as well as of regulatory factors having therapeutic utility.

Abstract: A substantially purified preparation containing one or more soluble Iron-Releasing Monokines and a method of preparing and using same are disclosed. The monokine is heat labile and is retained by ultrafiltration on a YM-10 membrane. Molecular exclusion chromatography of macrophage conditioned supernatant containing the monokine yields fractions in the 30,000 to 65,000 relative molecular weight range with iron-releasing activity. Kinetic studies show that the monokine is rapidly released from activated macrophages after triggering with bacterial endotoxin, reaching plateau levels within 2-4 hours. The response of cells to the monokine depends on both the dose of the monokine administered and the duration of its exposure. The Iron-Releasing Monokine is distinct from other factors secreted by activated macrophages, such as a cytolytic factor and Respiratory Inhibition Factor which causes reversible lesions in the electron transport chain.

Abstract: In the present investigation, we report the identification and cloning of a cDNA encoding an RNA splice variant of the rat D.sub.2 receptor cDNA.sup.12. This cDNA codes for a receptor isoform which is predominantly expressed in the brain and contains an additional 29 amino acids in the 3rd cytoplasmic loop, a region believed to be involved with G protein coupling. This is the first example of a novel G-protein coupled receptor isoform generated by alternative RNA splicing.

Abstract: This disclosure relates to new compounds and to a process for the controlled conversion of such compounds to produce a Protein that comprises an amino acid sequence which is useful as a precursor to human insulin or to a modified human insulin, the amino terminus portion of which sequence does not define a cathepsin C dipeptide removal stop point. The compounds have the formula Met-Y-Protein in which Y is Tyr or Arg.

Abstract: A high calcium chemically defined animal cell culture medium including vitamins A and D and a fatty acid or its ester. The medium is particularly adapted for the primary or secondary culture of epithelial cells. However, the medium may be utilized for establishing and maintaining cell lines, in particBACKGROUND OF THE INVENTIONThe United States government may have rights in this patent because of relevant developmental work supported by Research Grant No. CA43278 from National Institutes of Health.

Abstract: The present invention relates to a monoclonal antibody which specifically binds to a peptide having amino acid sequence (I) described below or having in part at least continuous 4 amino acid sequences of the amino acid sequence (I), and also to a process for producing a monoclonal antibody capable of specifically binding to the peptide represented by the following amino acid sequence:H-Y-Leu-Gly-Arg-X-Asp-Gly-Ser-Glu-OH (I)wherein X represents Glu or Gln and Y represents Trp or Arg.

Abstract: Specific antibody of the invention is capable of differentiating between malignant and benign tumors, and is obtained by culturing hybridoma cells prepared from tumor cells treated with a certain anti-tumor substance.

Abstract: A novel cell line for use as a parent for hybridoma preparation is provided. This cell line is derived from tumor cells, in particular human tumor cells, other than those originating from bone marrow cells. A method for establishing this cell line is also provided. By fusing this cell line with cells producing useful physiologically active substances, such as B cells immunized with an antigen, a hybridoma capable of active growth can be prepared. This hybridoma can be cultivated for the production of useful physiologically active substances.

Abstract: The present invention provides human B lymphoblastoid cell line AC-33, which is novel, and excellent in proliferativity and fusion capability, and works well as the parental line for obtaining a human monoclonal antibody-producing hybridoma. Said hybridoma possesses excellent proliferativity and stable antibody productivity, thus permitting efficient antibody production over a long period.

Abstract: Disclosed is a method for electroporation with which higher transformation efficiency may be attained than that attained by the conventional methods. In the method of electroporation, cells and DNAs are suspended in a buffer containing potassium ion as a cation and an amino acid ion and/or an organic acid ion as an anion, and substantially not containing chloride ion, and high voltage is applied thereacross.

Abstract: A monoclonal antibody which recognizes the N-terminal of .alpha.-atrial natriuretic polypeptide (.alpha.-ANP). A hybridoma producing said monoclonal antibody and a process for immunoassay of .alpha.-ANP are also provided.

Abstract: A liquid composition for nasal administration of polypeptide/s containing ammonium tartrate and a buffer together with optional adiuvants.

Abstract: The subject invention relates to a fibrin-specific monoclonal antibody wherein said monoclonal antibody does not crossreact with: (a) fibrinogen, (b) plasmin derived fibrinogen degradation products and (c) plasmin derived fibrin degradation products.

Abstract: Derivatives of glucagon-like peptide I (GLP-1) have been found to have insulinotropic activity. The invention pertains to such derivatives, and to the use of such derivatives as a potential therapy for Diabetes Mellitus.

Abstract: N,N-dimethylglycine, along or in combination with mitogen, increases the antibody productivity of antibody-producing cell cultures.

Abstract: A thrombolytic product comprising a fibrin-specific antibody substantially devoid of fibrinogen cross-reactivity coupled to a thrombolytic agent.

Abstract: Antibody preparation purified using immobilized protein A and yet substantially free of protein A that may have solubilized during the purificaiton process. The antibodies include less than 15 ng protein A per mg of antibody, preferably less than 1 ng/mg. Low protein A content is obtained by first contacting the antibodies and solubilized protein A with an ion exchange resin under conditions to adsorb both. The antibodies and protein A are then sequentially eluted under conditions of increasing ionic strength.

Abstract: A method for obtaining permanently culturable human and animal cell lines, as well as uses for these cell lines, are disclosed. The method involves fusing cells of a non-immortal cell line with cytoplasts or cytoplasma fractions of "immortal", transformed cells such as immortal myeloma cells, ascites-tumor cells or Epstein Barr Virus infected cells. Once fusion takes place the product is a permanently culturable variant of the previously normal cell line.

Abstract: The present invention relates to methods of producing an antibody highly specific to a low-molecular weight substance such as amino acids, peptides, amines, steroids, etc. The invention also relates to a process for producing the same by forming a complex of the substance with colloidal metal particles and sensitizing a mammal with the complex. The antibody can be in the form of an antiserum containing the antibody. Since the antibody has a high specificity to the intended low-molecular weight substance, it is useful as a reagent for various immunohistochemical methods and immunoassays.